BioPhy
BioPhy is a Philadelphia-based enterprise AI platform that combines a proprietary knowledge-graph predictive engine (BioLogicAI) and a domain-specific generative AI (BioPhyRx) to modernize regulatory, validation, quality, and manufacturing operations for large pharmaceutical and life sciences companies, sold via direct enterprise SaaS contracts.
- Company typePrivate
- Founded2020
- HeadquartersPhiladelphia, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BioPhy does
BioPhy (legal entity Trial Risk Index, Inc.) is a Philadelphia-based enterprise AI platform company founded in 2020 by Dave Latshaw II, PhD, that sells modular AI software to pharmaceutical and life sciences organizations to modernize compliance, regulatory, validation, manufacturing, and supply-chain operations. The platform combines two proprietary in-house AI systems: BioLogicAI, a predictive AI engine powered by what the company describes as the industry's most extensive drug development knowledge graph and validated across 1,500+ clinical trials with a claimed 80% success rate; and BioPhyRx, a purpose-built domain-specific generative AI language system that analyzes scientific literature, clinical trials, FDA guidelines, and regulatory documents with cited sources to limit hallucination. Modular products include the Regulatory Gap Analyzer, SOP Consolidator, Validation Accelerator, Quality Compliance, Deep Research, Validation Requirement Navigator, and Document Search.
BioPhy monetizes via enterprise SaaS contracts sold through direct field sales, with no public pricing, a 'Request a Demo' go-to-motion, and a dedicated SVP of Sales. Customers include an unnamed top-10 US pharma (where BioPhy reportedly avoided $50M/day in manufacturing delays), a large European pharma, a Big 3 consulting firm serving life sciences, and the nonprofit Every Cure. BioPhy is SOC 2, HIPAA, and GDPR certified, has $11.1M in disclosed funding across two rounds (Nov 2023 and Mar 2025) led by Metrodora Ventures, Audere Capital, and TRCM, won Fast Company's 2024 World Changing Ideas Award, and was acquired by Intrinsic Clinical Systems on February 2, 2026, rebranding to Intrinsic BioPhy in June 2026.
BioPhy firmographics
Firmographics- Name
- BioPhy
- Legal name
- Trial Risk Index, Inc.
- Website
- https://biophy.ai
- Company type
- Private
- Founded year
- 2020
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- BioPhy is a Philadelphia-based enterprise AI platform that combines a proprietary knowledge-graph predictive engine (BioLogicAI) and a domain-specific generative AI (BioPhyRx) to modernize regulatory, validation, quality, and manufacturing operations for large pharmaceutical and life sciences companies, sold via direct enterprise SaaS contracts.
- Ownership category
- akta.pro rank
BioPhy industry classification
Industry- Product category
- Pharmaceutical AI Software
- NAICS
- Software Publishers (51321), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)
Keywords
Where BioPhy is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioPhy business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Enterprise SaaS / Subscription for AI Platform Modules: BioPhy delivers a suite of modular AI solutions across pharmaceutical operations. The platform is sold as enterprise software, likely on a subscription or contract basis, with modules for Regulatory Gap Analyzer, SOP Consolidator, and Validation Accelerator. Pricing is quote-based; no public price list is available. The company serves large pharmaceutical companies and biotech firms under multi-year contractual arrangements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise modular AI platform — no public tier structure disclosed |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
BioPhy product offering
Product offeringCore offering
BioPhy provides an enterprise AI platform for pharmaceutical operations that combines BioLogicAI (a proprietary predictive AI engine powered by the industry's most extensive knowledge graph) and BioPhyRx (a purpose-built generative AI language system). The platform delivers modular solutions including Regulatory Gap Analyzer, SOP Consolidator, Validation Accelerator, Quality Compliance, Deep Research, and Validation Requirement Navigator to modernize pharma's compliance, quality, manufacturing, and supply-chain infrastructure.
Product overview
BioPhy is an enterprise AI platform for pharmaceutical operations that combines two core AI technologies: BioLogicAI (a proprietary predictive AI engine powered by the industry's most extensive knowledge graph for assessing therapy viability and optimizing trial designs) and BioPhyRx (a purpose-built generative AI language system for regulatory research and document analysis). The platform delivers modular AI solutions including Regulatory Gap Analyzer, SOP Consolidator, Validation Accelerator, Quality Compliance, Deep Research, and Validation Requirement Navigator. Built by the team behind J&J's $100M+ AI savings, the platform targets quality, compliance, manufacturing, and supply-chain challenges across the pharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Brands
- BioLogicAI: Proprietary AI engine powered by the industry's most extensive knowledge graph providing unmatched insights and predictions for drug development, accurately assessing therapy viability, optimizing trial designs, and prioritizing drug candidates.
- BioPhyRx
Products and services
- BioLogicAI A proprietary AI engine powered by the industry's most extensive knowledge graph that provides insights and predictions for drug development. It assesses the viability of potential therapies, optimizes trial designs, and prioritizes the most promising drug candidates for pharmaceutical companies.
- BioPhyRx A purpose-built generative AI language system designed for the drug development industry. It completes function-specific workflows including regulatory guidance comparison, research, and document analysis, providing transparency, accuracy, and domain-specific expertise for pharmaceutical and life sciences teams.
- Regulatory Gap Analyzer Automatically identifies misalignments between SOPs and regulations with compliance risk scoring and remediation recommendations. Delivers a 65% reduction in manual review time and is intended for Quality Operations, Document Control, and Site Leads at pharmaceutical companies.
- SOP Consolidator Eliminates document duplication across departments and regions through document similarity analysis, cross-regional consistency checks, and version control monitoring. Designed for Manufacturing, Validation, and Engineering Teams in pharmaceutical organizations.
- Validation Accelerator Streamlines IQ/OQ/PQ validation cycles, saving months per product through automated protocol generation, traceability matrix creation, and real-time validation monitoring. Essential for expediting product launch timelines in pharmaceutical manufacturing.
- Validation Requirement Navigator AI chatbot and network graph capability for navigating validation requirements, with the ability to save, edit, and delete analyses. Includes improved summarization options and optimized retrieval algorithms for pharmaceutical validation workflows.
- Deep Research Automates generation of research plans for user-specified topics and executes large-scale analysis to generate comprehensive reports. Features updated backend models for handling complex research tasks and document drafting in pharmaceutical and regulatory contexts.
Quantifiable outcome
- 80% clinical trial outcome prediction success rate across over 1,500 trials
- +5 more outcomes
Companies that use BioPhy
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
BioPhy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature10 records
BioPhy partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Intrinsic Clinical SystemsflagshipBioPhy was acquired by Intrinsic Clinical Systems on February 2, 2026. The transaction expands Intrinsic Clinical Systems' capabilities in regulatory intelligence and quality analytics, integrating BioPhy's regulatory research engine and QMS gap analysis solutions into its platform. Financial terms were not disclosed. Post-acquisition, BioPhy was rebranded as 'Intrinsic BioPhy' (per v5.6 release notes, June 12, 2026).
- Every CurecoreEvery Cure deployed BioPhy's AI platform to accelerate its mission of repurposing drugs for untreated diseases. This nonprofit organization focuses on finding new uses for existing drugs, leveraging BioPhy's AI capabilities to analyze and predict therapeutic outcomes at scale.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
BioPhy competitors and assessment
Company assessmentBroad incumbents
- Veeva Systems: Largest pure-play cloud software provider for the life-sciences industry, offering regulatory, quality, clinical, and commercial solutions. Overlaps with BioPhy in regulatory/quality/compliance software serving global pharma customers.
- IQVIA: Global clinical research and healthcare analytics leader with AI/ML-driven clinical trial and commercial solutions. Comparable to BioPhy in clinical trial prediction and life-sciences data analytics, but at vastly greater scale.
Direct peers
- Benchling: Cloud-based R&D platform for life sciences covering molecular biology, process development, and analytical workflows. Comparable to BioPhy as a SaaS platform digitizing pharma/biotech R&D and operations with workflow and data-capture modules.
- Schrödinger: AI/ML-driven computational drug discovery platform combining physics-based modeling with predictive analytics. Comparable to BioPhy's BioLogicAI in using proprietary AI to optimize candidate selection and trial design for pharma clients.
- Recursion: AI-driven drug discovery company using high-throughput biology and machine learning to identify novel therapeutics. Comparable to BioPhy in applying AI/ML to accelerate drug development pipelines, though Recursion is a pipeline developer rather than a software vendor.
- Insilico Medicine: AI-driven drug discovery company applying generative AI and predictive models to identify novel targets and design new molecules. Comparable to BioPhy in combining predictive and generative AI for pharma R&D.
Emerging players
- CytoReason: AI platform for cell-level disease modeling and drug development decision support used by top-10 pharma. Comparable to BioPhy's BioLogicAI in applying predictive AI to optimize drug development strategy and trial design.
- Owkin: AI/ML platform applying federated learning to clinical and biomedical data for pharma R&D and clinical trial optimization. Comparable to BioPhy as an AI-driven life-sciences analytics platform partnering with major pharma.
- Saama Technologies: AI/analytics platform purpose-built for clinical development and commercial operations in life sciences. Comparable to BioPhy in serving pharma operations, clinical, and regulatory workflows with AI-enabled SaaS.
- Tempus AI: AI-driven precision medicine platform combining multimodal clinical and molecular data for pharma R&D and clinical decision support. Comparable to BioPhy in applying AI to optimize pharma R&D decisions and improve trial outcomes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioPhy social profiles
Digital presenceBioPhy compliance and trust
Trust signalCompliance3 records
BioPhy financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioPhy leadership team
Management profileNumber of profiles
Profiles2 records
BioPhy funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioPhy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioPhy
What does BioPhy do?
BioPhy provides an enterprise AI platform for pharmaceutical operations that combines BioLogicAI (a proprietary predictive AI engine powered by the industry's most extensive knowledge graph) and BioPhyRx (a purpose-built generative AI language system). The platform delivers modular solutions including Regulatory Gap Analyzer, SOP Consolidator, Validation Accelerator, Quality Compliance, Deep Research, and Validation Requirement Navigator to modernize pharma's compliance, quality, manufacturing, and supply-chain infrastructure.
Is BioPhy a public or private company?
BioPhy is a private company. It is classified as corporate owned and is currently acquired.
When was BioPhy founded?
BioPhy was founded in 2020. It employs 1 to 10 people.
Where is BioPhy based?
BioPhy is headquartered in Philadelphia, United States, in the North America region.
How does BioPhy make money?
One revenue line is on record: enterprise SaaS / Subscription for AI Platform Modules.
Who are BioPhy's main competitors?
Broad incumbents on record are Veeva Systems and IQVIA. Direct peers are Benchling, Schrödinger, Recursion and Insilico Medicine. Emerging players are CytoReason, Owkin, Saama Technologies and Tempus AI.
Does BioPhy have an API?
No public API is recorded for BioPhy.
What industry is BioPhy in?
BioPhy's product category is Pharmaceutical AI Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 51321 and its SIC code is 8731.